Seqens Seqens

X
[{"orgOrder":0,"company":"ORAPHARMA","sponsor":"Bausch Health","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"New Clinical Study Suggests the Use of OraPharma\u2019s ARESTIN\u00ae (minocycline HCl) Microspheres, 1mg May Decrease Certain Pathogens in Adults with Periodontitis","therapeuticArea":"Dental and Oral Health","highestDevelopmentStatus":"Approved","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"May 2023","url1":"","url2":"","graph1":"Small molecule","graph2":"ORAPHARMA"}]

Find Clinical Drug Development Pipelines & Deals | PipelineProspector

Loading...
Filters Filter
×
FILTER:
filter Company
    filter Sponsor
      filter Country
        filter Product Type
          filter News Type

            Active Filter(s):

            Product Type

            Companies

            Details:

            ARESTIN (minocycline HCl) Microspheres, 1mg is indicated as an adjunct to scaling and root planing (SRP) procedures for reduction of pocket depth in patients with adult periodontitis.

            Lead Product(s): Minocycline Hydrochloride

            Therapeutic Area: Dental and Oral Health Product Name: Arestin

            Highest Development Status: Approved Product Type: Small molecule

            Partner/Sponsor/Collaborator: Bausch Health

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable May 18, 2023

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity
            Post Enquiry
            POST ENQUIRY